Search

But increase in cardiovascular disease mortality seen after more than 20 years of follow-up among older women For postmenopausal women, calcium and vitamin D (CaD) supplements may reduce cancer mortality and increase cardiovascular disease (CVD) mortality after more than 20 years of follow-up, according to a study published online March 12 in the Annals of Internal...

A cohort study finds that histologic subtype is the main factor associated with survival disparities between Black and White uterine cancer patients. Survival disparities have existed between non-Hispanic Black and White uterine cancer patients for decades, with an increased likelihood of aggressive disease, recurrence, and death among Black patients.  A cohort study published in JAMA...

In the IDEA trial, postmenopausal patients aged 50–69 years with pT1N0 unifocal invasive breast cancer who did not receive radiotherapy achieved a high level of disease control after 5 years. For over three decades, radiotherapy has been an essential part of the treatment following breast-conserving surgery (BCS) for patients with early-stage breast cancer. Recent studies...

In a retrospective cohort study, racial disparities in the use of medications and interventions near end of life were observed among patients with advanced gynecologic cancer.  Palliative medicine improves outcomes in patients with gynecologic malignancies. Studies on palliative medicine in cancer have minimal representation from minority groups. A retrospective cohort study published in the journal...

by Roger Mosley A retrospective cohort study analyzing a large dataset found that atopic dermatitis is associated with a significant increase in the risk of various skin cancer types. Atopic dermatitis (AD) causes scaly, itchy patches and is relatively benign. Although its pathogenesis is not fully understood, it is known that disruption in skin barrier...

Intermittent relacorilant + nab-paclitaxel improves survival outcomes and response duration in platinum-resistant/refractory ovarian cancer compared to nab-paclitaxel monotherapy, according to the results of a phase II study. Treatment of advanced epithelial ovarian cancer is challenging. Most patients who initially respond to platinum-based chemotherapy eventually develop resistance. Patient outcomes are poor in platinum-resistant/refractory ovarian cancer treated...

DRL-Trastuzumab was found to have similar efficacy, safety, pharmacokinetics, and immunogenicity as Herceptin in HER2-positive breast cancer patients in a randomized, double-blind study. Trastuzumab, marketed under the brand name Herceptin, is a standard therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug DRL_TZ, a potential trastuzumab biosimilar to Herceptin, was developed...

Gynecological cancer uniquely affects health-related quality of life. A 2023 literature review reports that treatment side effects such as fatigue, pain, and sexual dysfunction impact psychological well-being. Younger patients and those in advanced stages generally experience greater challenges. Tailoring treatment approaches and implementing supportive care can help improve health-related quality of life for survivors. Gynecological...

A small cohort study found that p53 null mutations confer a particularly severe prognosis in high-grade serous ovarian cancers. Epithelial ovarian cancer is the fifth most common cause of female cancer-related mortality in the developed world. The most frequent type of epithelial ovarian cancer is high-grade serous ovarian cancer (HGSOC).  A cohort study published in...

A phase III study suggests that olaparib-bevacizumab is not only effective for high-risk (of relapse) HRD-positive tumors but is even more effective for low-risk patients in prolonging progression-free survival. Cure is the ultimate goal of ovarian cancer treatment; however, ovarian cancer patients are often first diagnosed at advanced stages, with an increased risk of relapse....